{"id":10816,"date":"2019-11-29T10:52:58","date_gmt":"2019-11-29T09:52:58","guid":{"rendered":"https:\/\/udic.es\/?p=10816"},"modified":"2024-02-14T15:53:28","modified_gmt":"2024-02-14T14:53:28","slug":"una-terapia-innovadora-y-sorprendente-en-parkinson","status":"publish","type":"post","link":"https:\/\/udic.es\/ca\/una-terapia-innovadora-y-sorprendente-en-parkinson\/","title":{"rendered":"Una ter\u00e0pia en Parkinson innovadora i sorprenent."},"content":{"rendered":"
El nostre equip iniciar\u00e0 l’avaluaci\u00f3 d’un f\u00e0rmac nou que s’administra per via intratecal. Es tracta d’un assaig de fase I amb un oligonucle\u00f2tid, administrat per via intratecal, que pret\u00e9n reduir la formaci\u00f3 de alfasinucleina, per inhibici\u00f3 de l’gen LRKK2.<\/p>\n","protected":false},"excerpt":{"rendered":"
El nostre equip iniciar\u00e0 l’avaluaci\u00f3 d’un f\u00e0rmac nou que s’administra per via intratecal. Es tracta d’un assaig de fase I amb un oligonucle\u00f2tid, administrat per via intratecal, que pret\u00e9n reduir la formaci\u00f3 de alfasinucleina, per inhibici\u00f3 de l’gen LRKK2.<\/p>\n","protected":false},"author":4,"featured_media":9344,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[125],"tags":[],"class_list":["post-10816","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-parkinson-ca"],"yoast_head":"\n